Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07228078
PHASE2
Open-Label Extension Protocol to SNK01-AD01 Study
Sponsor: NKGen Biotech, Inc.
View on ClinicalTrials.gov
Summary
Open-Label Extension Protocol to SNK01-AD01 Study
Official title: An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)
Key Details
Gender
All
Age Range
40 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-06-30
Completion Date
2028-04
Last Updated
2025-11-13
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
SNK01
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
Locations (1)
Behavioral Research Specialists, LLC
Glendale, California, United States